SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on August 28, 2017. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of materials rather than a financial statement.
Material Changes
No material financial changes versus a prior period are reported in this document. The filing focuses on the disclosure of non-filed materials.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure (Item 7.01): The Company attached a presentation (Exhibit 99.1) and a fact sheet (Exhibit 99.2) dated August 2017. These materials are used by management in meetings to describe the Company.
- Legal Status of Exhibits: The information contained in Item 7.01 and the attached exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly set forth by specific reference.
- Signatory: The report was signed by Andrew R. Boll, Chief Financial Officer.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation) and Exhibit 99.2 (Fact Sheet) for forward-looking statements or strategic updates, noting they are not legally "filed" documents.
- Confirm that the company name is Imprimis Pharmaceuticals, Inc. (Note: The request metadata referenced "Harrow, Inc.", but the filing text explicitly identifies Imprimis Pharmaceuticals, Inc.).
- Review subsequent filings to determine if the information in the August 2017 presentation has been incorporated by reference or updated.